A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Incyte

Status and phase

Completed

Phase 2

Phase 1

Conditions

Metastatic Cancer

Advanced Malignancies

Treatments

Drug: INCAGN01949

Study type

Interventional

Funder types

Industry

Identifiers

NCT02923349

INCAGN 1949-101

2016-002079-93 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.

Enrollment

87 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.
Part 1: Subjects with advanced or metastatic solid tumors.
Part 2: Subjects with advanced or metastatic adenocarcinoma of the endometrium, ovarian cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer.
Presence of measureable disease based on RECIST v1.1.
Eastern Cooperative Oncology Group performance status 0 or 1.

Exclusion criteria

Laboratory and medical history parameters not within the protocol-defined range.
Receipt of anticancer medications or investigational drugs within the protocol-defined intervals before the first administration of study drug.
Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.
Receipt of a live vaccine within 30 days of planned start of study drug.
Active autoimmune disease that required systemic treatment in the past.